Multicenter development and validation of a probability-based model to diagnose Lewy body disease using ¹²³I-meta-iodobenzylguanidine
The probability-based <sup>123</sup>I-mIBG model reliably differentiated LBD from other diseases. Standardization among sites supports global applicability and reflects real-world clinical practice.
Authors
- Naoki Shirasaki
- Junji Komatsu (ORCID: https://orcid.org/0000-0002-5150-6322)
- Takeshi Matsumura (ORCID: https://orcid.org/0000-0002-4134-2635)
- M. Noguchi-Shinohara
- Gemma Roberts (ORCID: https://orcid.org/0000-0002-6445-4023)
- A. Goldzier Thomas
- Maria Silvia De Feo (ORCID: https://orcid.org/0000-0003-3216-4838)
- Wanda Acampa (ORCID: https://orcid.org/0000-0003-2187-4076)
- Hiroshi Wakabayashi
- Roberta Assante
- Seigo Kinuya
- Kenjiro Ono
- Satoshi Orimo
- Kunihiko Yokoyama
- Mitsuhiro Yoshita
Institutions
- Kanazawa University (JP)
- University College Hospital (GB)
- National Hospital Organization (JP)
- Public Central Hospital of Matto Ishikawa (JP)
- National Institute of Health Sciences (JP)
- Shiga Medical Center (JP)
- University College London (GB)
- University of Naples Federico II (IT)
- Newcastle University (GB)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1007/s00259-025-07706-0
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kanazawa University
- Japan Society for the Promotion of Science